Press Coverage
Sofinnova Capital
Henrijette Richter discusses R&D in plenary at WuXi Global Forum
Related Deal lead
Henrijette RichterRelated Strategy
CapitalHenrijette Richter, managing partner at Sofinnova Partners, participated in the opening plenary panel discussion at the WuXi Global Forum 2022 on January 10. Marking the 10th anniversary of the event, the panel, led by Jorge Conde, general partner at Andreessen Horowitz, took a look back at 10 years of breakthroughs that are changing the game in R&D productivity before turning their focus on the future. Henrijette joined David Berry, founder and CEO of Valo Health; Diego Miralles, CEO of Laronde, and Roger Perlmutter, chairman and CEO of Eikon Therapeutics.
View the replay here.
Related News
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion
How a Sofinnova Partner's thesis became a $165M biotech
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases